F1174V mutation alters the ALK active conformation in response to Crizotinib in NSCLC: Insight from molecular...

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Crizotinib is a key treatment for anaplastic lymphoma kinase-positive non-small cell lung carcinoma (NSCLC).
• Acquired resistance to Crizotinib, often due to mutations like F1174V, limits treatment efficacy.
• The specific molecular mechanisms underlying F1174V-mediated Crizotinib resistance are not fully understood.

Purpose of the Study:

• To investigate the structural and dynamic effects of the F1174V mutation on the anaplastic lymphoma kinase (ALK) domain.
• To elucidate the molecular mechanisms responsible for Crizotinib resistance conferred by the F1174V mutation.

Main Methods:

• Utilized molecular dynamic (MD) simulations to analyze the wild-type and F1174V mutant ALK kinase domain.
• Performed structural analyses to identify conformational and interaction changes induced by the mutation.

Main Results:

• The F1174V mutation induces significant secondary structure alterations within the ALK kinase domain.
• These structural changes lead to local conformational shifts and increased free energy in the mutant complex compared to the wild-type.
• The mutation disrupts key interactions essential for the active conformation of ALK.

Conclusions:

• The F1174V mutation confers Crizotinib resistance by altering ALK structure and dynamics.
• This study provides a molecular basis for understanding F1174V-mediated resistance.
• Findings can guide the development of next-generation ALK inhibitors to overcome resistance.